Accelerating HIV prevention in high-risk prison environments - with 9,500 inmates and a 10.3% HIV prevalence, 75% of whom have a history of injecting drug use (IDU), including up to 1/3 within-prison,…

Active Project Grant Awarded Last action

Award ID
R01DA062557
Recipient
Awarding agency
Obligated
$2,517,181

Award facts

Assistance listing
93.279 Drug Use and Addiction Research Programs
Completion date 25% complete
Place of performance
New Haven, CT 06510, USA

Award details come from USAspending.gov.

Description

Accelerating HIV prevention in high-risk prison environments - with 9,500 inmates and a 10.3% HIV prevalence, 75% of whom have a history of injecting drug use (IDU), including up to 1/3 within-prison, kyrgyzstan's prisons are crucial for HIV control efforts. Previous interventions failed to increase OAT uptake, encountering significant barriers, including stigma and drug use stigma in prison. During the K01 study, our multidisciplinary kyrgyz team CO-developed hope (help OAT prison engagement), a 6-week intervention tailored to the prison HIV high-risk environment. Hope incorporates several evidence-informed elements, including a) HIV screening followed by HIV literacy session, B) assessing depressive and anxiety symptoms and positive mental health elements (e.g., quality of life, social support, and self-reported resilience), followed by mindfulness enhancement sessions, and C) addiction literacy and self-management. Hope also increases self-efficacy through empowerment-based skills-building, including managing OAT stigma and conflict in a high-risk prison environment and resource utilization. Each of hope's 12 thematic components comprises a mini-lecture, a group discussion, and group exercises practicing targeted skills. We plan to compare hope to an information-only control using a type 1, hybrid implementation trial to evaluate the effectiveness of hope for HIV prevention in prison, including uptake of OAT/SSP services, combined with exploration of implementation factors that may contribute to intervention effects and a future scale-up. We aim (1) to conduct a cluster randomized controlled trial of the hope intervention to determine its effectiveness for HIV prevention (i.e., OAT and SSP use) over 12 months. We will enroll 360 participants who have over 1 year remaining before release across 20 housing units (each HU has ~100 PIP) from four male prisons in kyrgyzstan. Assessments will occur at baseline, 3, 6, 9, and 12 months. The primary outcome is OAT start; secondary outcomes include other HIV risk-reduction strategies like SSP use and engagement in HIV risk behaviors. Aim 2 is to conduct a combination of qualitative interviews and focus group discussions to examine implementation factors associated with the effectiveness of hope, its uptake and scale-up from the perspective of multi-level stakeholders. Aim 3: use results from aim 1 to conduct a cost-effectiveness analysis (CEA) of hope relative to the control for reducing HIV transmission and improving quality of life among PIP. This study is relevant to the US (and global) public health as findings will provide effectiveness, implementation and cost-effectiveness data for low-resource settings where pwid are concentrated in prison settings.

Transactions

Action Obligated Date
Amendment $208,283
Amendment $378,899
Amendment $378,899
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $33,770
Amendment $33,770
Amendment $86,313
Amendment $137,088
Amendment $86,313
Amendment $137,088
Amendment $518,379
Original award $518,379
Show all 20

Subawards

Subrecipient Amount Awarded
Public Foundation "Den Sooluk Nuru" "All work for this sub-award will be conducted under the direction of the MPIs, contact MPI Dr Julia Rozanova, and MPI in Kyrgyz Republic, Dr Natalya Shumskaya.… $137,088
Ukrainian Institute On Public Health Policy "Drs. Zeziulin, Dumchev and the UIPHP team will work with Dr Rozanova to carry out the Specific Aims of this grant in Ukraine. Specifically UIPHP will serve… $86,313

Quick answers

Who received award R01DA062557?

R01DA062557 was awarded to Yale Univ by National Institute on Drug Abuse (National Institutes of Health) on August 15, 2025.

How much is award R01DA062557 worth?

$2,517,181 has been obligated on R01DA062557.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award